Pancreatic ductal adenocarcinoma – commonly referred to as pancreatic cancer, is a devastating disease with around 46.000 new cases and 40.000 deaths each year in the US (9). The illness has a median survival not exceeding 4 months if left untreated. Standard of care is the chemotherapy Gemzar® (gemcitabine), either alone or in combination with other drugs. Gemzar® has only a limited effect on survival. There is obviously a huge unmet medical need for new treatment options for pancreatic cancer despite recent advances (10) such as Tarceva®, FOLFIRINOX and Abraxane®.
Axcentua is currently investigating the therapeutic potential of genistein SSDH in combination with gemcitabine in the treatment of pancreatic cancer. This indication was selected as it has been repeatedly shown in animal models of pancreatic cancer that genistein both inhibit metastasis (11, 12) and enhance the effect of the chemotherapeutic compound gemcitabine (13) today’s standard of care in metastatic pancreatic cancer. In addition, genistein has been shown to enhance the effect of other chemotherapies (14, 15) in animal models of pancreatic cancer